Boosting serotonin in the brain: Is it time to revamp the treatment of depression?

Mariana P. Torrente, Alan J. Gelenberg, Kent Vrana

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Abnormalities in serotonin systems are presumably linked to various psychiatric disorders including schizophrenia and depression. Medications intended for these disorders aim to either block the reuptake or the degradation of this neurotransmitter. In an alternative approach, efforts have been made to enhance serotonin levels through dietary manipulation of precursor levels with modest clinical success. In the last 30 years, there has been little improvement in the pharmaceutical management of depression, and now is the time to revisit therapeutic strategies for the treatment of this disease. Tryptophan hydroxylase (TPH) catalyzes the first and rate-limiting step in the biosynthesis of serotonin. A recently discovered isoform, TPH2, is responsible for serotonin biosynthesis in the brain. Learning how to activate this enzyme (and its polymorphic versions) may lead to a new, more selective generation of antidepressants, able to regulate the levels of serotonin in the brain with fewer side effects.

Original languageEnglish (US)
Pages (from-to)629-635
Number of pages7
JournalJournal of Psychopharmacology
Volume26
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Serotonin
Depression
Brain
Tryptophan Hydroxylase
Antidepressive Agents
Neurotransmitter Agents
Psychiatry
Schizophrenia
Protein Isoforms
Learning
Enzymes
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Torrente, Mariana P. ; Gelenberg, Alan J. ; Vrana, Kent. / Boosting serotonin in the brain : Is it time to revamp the treatment of depression?. In: Journal of Psychopharmacology. 2012 ; Vol. 26, No. 5. pp. 629-635.
@article{46fd6e7826154c4380e55ca32301e805,
title = "Boosting serotonin in the brain: Is it time to revamp the treatment of depression?",
abstract = "Abnormalities in serotonin systems are presumably linked to various psychiatric disorders including schizophrenia and depression. Medications intended for these disorders aim to either block the reuptake or the degradation of this neurotransmitter. In an alternative approach, efforts have been made to enhance serotonin levels through dietary manipulation of precursor levels with modest clinical success. In the last 30 years, there has been little improvement in the pharmaceutical management of depression, and now is the time to revisit therapeutic strategies for the treatment of this disease. Tryptophan hydroxylase (TPH) catalyzes the first and rate-limiting step in the biosynthesis of serotonin. A recently discovered isoform, TPH2, is responsible for serotonin biosynthesis in the brain. Learning how to activate this enzyme (and its polymorphic versions) may lead to a new, more selective generation of antidepressants, able to regulate the levels of serotonin in the brain with fewer side effects.",
author = "Torrente, {Mariana P.} and Gelenberg, {Alan J.} and Kent Vrana",
year = "2012",
month = "5",
day = "1",
doi = "10.1177/0269881111430744",
language = "English (US)",
volume = "26",
pages = "629--635",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "5",

}

Boosting serotonin in the brain : Is it time to revamp the treatment of depression? / Torrente, Mariana P.; Gelenberg, Alan J.; Vrana, Kent.

In: Journal of Psychopharmacology, Vol. 26, No. 5, 01.05.2012, p. 629-635.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Boosting serotonin in the brain

T2 - Is it time to revamp the treatment of depression?

AU - Torrente, Mariana P.

AU - Gelenberg, Alan J.

AU - Vrana, Kent

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Abnormalities in serotonin systems are presumably linked to various psychiatric disorders including schizophrenia and depression. Medications intended for these disorders aim to either block the reuptake or the degradation of this neurotransmitter. In an alternative approach, efforts have been made to enhance serotonin levels through dietary manipulation of precursor levels with modest clinical success. In the last 30 years, there has been little improvement in the pharmaceutical management of depression, and now is the time to revisit therapeutic strategies for the treatment of this disease. Tryptophan hydroxylase (TPH) catalyzes the first and rate-limiting step in the biosynthesis of serotonin. A recently discovered isoform, TPH2, is responsible for serotonin biosynthesis in the brain. Learning how to activate this enzyme (and its polymorphic versions) may lead to a new, more selective generation of antidepressants, able to regulate the levels of serotonin in the brain with fewer side effects.

AB - Abnormalities in serotonin systems are presumably linked to various psychiatric disorders including schizophrenia and depression. Medications intended for these disorders aim to either block the reuptake or the degradation of this neurotransmitter. In an alternative approach, efforts have been made to enhance serotonin levels through dietary manipulation of precursor levels with modest clinical success. In the last 30 years, there has been little improvement in the pharmaceutical management of depression, and now is the time to revisit therapeutic strategies for the treatment of this disease. Tryptophan hydroxylase (TPH) catalyzes the first and rate-limiting step in the biosynthesis of serotonin. A recently discovered isoform, TPH2, is responsible for serotonin biosynthesis in the brain. Learning how to activate this enzyme (and its polymorphic versions) may lead to a new, more selective generation of antidepressants, able to regulate the levels of serotonin in the brain with fewer side effects.

UR - http://www.scopus.com/inward/record.url?scp=84861792389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861792389&partnerID=8YFLogxK

U2 - 10.1177/0269881111430744

DO - 10.1177/0269881111430744

M3 - Review article

C2 - 22158544

AN - SCOPUS:84861792389

VL - 26

SP - 629

EP - 635

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 5

ER -